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Abstract
Obesity induces chronic inflammation and is an established risk and progression factor for triple-
negative breast cancers, including basal-like (BL) and claudin-low (CL) subtypes. We tested the 
effects of dietary supplementation with ethyl esters of the marine-derived anti-inflammatory 
omega-3 fatty acids eicosapentaenoic and docosahexaenoic acid (EPA+DHA; Lovaza®) on growth 
of murine BL and CL mammary tumors. Female ovariectomized C57BL/6 mice were fed a control 
diet or a diet-induced obesity (DIO) diet with or without EPA+DHA (0.025%, resulting in blood 
levels of EPA and DHA comparable to women taking Lovaza 4 g/day) for 6 weeks. All mice were 
then orthotopically injected with Wnt-1 cells (a BL tumor cell suspension derived from MMTV-
Wnt-1 transgenic mouse mammary tumors) or M-Wnt cells (a CL tumor cell line cloned from the 
Wnt-1 tumor cell suspension). Mice were killed when tumors were 1 cm in diameter. EPA+DHA 
supplementation did not significantly impact Wnt-1 or M-Wnt mammary tumor growth in 
normoweight control mice. However, EPA+DHA supplementation in DIO mice reduced growth of 
Wnt-1 and M-Wnt tumors; reduced leptin:adiponectin ratio and pro-inflammatory eicosanoids in 
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the serum; improved insulin sensitivity; and decreased tumoral expression of cyclooxygenase-2 
and phospho-p65. Thus, EPA+DHA supplementation in mouse models of postmenopausal BL and 
CL breast cancer offsets many of the pro-tumorigenic effects of obesity. These preclinical findings, 
in combination with results from parallel biomarker studies in women, suggest EPA+DHA 
supplementation may reduce the burden of BL and CL breast cancer in obese women.
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Introduction
Obesity induces chronic inflammation in adipose and other tissues, resulting in an increase 
in multiple factors known to promote breast cancer development and progression. These 
obesity-related factors include insulin, bioavailable insulin-like growth factor (IGF)-1, and 
pro-inflammatory adipokines and cytokines, as well as increased mammary gland expression 
of aromatase and markers of inflammation, proliferation and cell survival [1]. Obesity is 
associated with poorer prognoses of breast cancer, independent of menopausal status and 
across subtypes [2], including the triple-negative breast cancer (TNBC) subtype. TNBC, 
which primarily encompasses both the basal-like (BL) and claudin-low (CL) breast cancer 
subtypes, is highly aggressive and is associated with a higher risk of distant metastases and 
mortality [3]. Although significant (>10%) weight loss is associated with favorable 
modulation of intermediates known to promote breast cancer in animal models and in human 
interventional studies [4-5], achievement and maintenance of significant weight loss is an 
elusive goal for most obese individuals. Consequently, improved treatment regimens for the 
prevention of TNBC recurrence and mortality, particularly in the obese patient population, 
are urgently needed.
Omega-3 fatty acids and omega-6 fatty acids are long-chain polyunsaturated fatty acids 
incorporated into lipid membranes, whose derivatives play major roles in inflammation, cell 
membrane fluidity, and cell signaling [6]. Omega-3 and -6 fatty acids also have profound 
effects on insulin sensitivity and can modulate cancer-related cell proliferation and survival 
pathways [7]. Epidemiological studies suggest an inverse correlation between omega-3 
levels (including the ratio of omega-3 to omega-6 intake and the ratio of phospholipid 
omega-3 to omega-6 fatty acid levels in erythrocytes or adipocytes and breast cancer risk 
and/or progression [8-9].
In the US, most omega-3 fatty acids obtained from the diet are from alpha-linolenic acid, 
commonly found in plant oils and nuts. Due to poor conversion efficiency, less than 5% of 
alpha-linolenic acid is converted into the biologically relevant long-chain fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that impact cell signaling. 
Lovaza® is a highly concentrated combination of marine-derived omega-3 ethyl esters, 
principally EPA and DHA, approved in the US for reducing hypertriglyceridemia. Although 
its impact on cancer risk or progression has not been previously reported, Lovaza 
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(henceforth referred to as EPA+DHA) has been suggested for inclusion in future breast 
cancer chemoprevention trials [10].
We have previously demonstrated the beneficial effects of calorie restriction on murine BL 
and CL mammary tumors [11]; both of these breast cancer subtypes are associated with an 
increase in pro-inflammatory markers [12-13]. Given that omega-3 fatty acids mimic many 
of the anti-inflammatory and metabolic effects of calorie restriction, we hypothesized that 
dietary supplementation with EPA+DHA would produce a favorable blood and mammary 
tissue profile of obesity-related inflammatory and metabolic markers and reduce progression 
of CL and/or BL mammary tumors. We tested this hypothesis using our Wnt-driven mouse 
models of BL and CL mammary cancer in preclinical tumor and biomarker studies 
performed in parallel with human biomarker trials [14]. Specifically, we assessed the effects 
of dietary supplementation with EPA+DHA, in the context of a control or diet-induced 
obesity (DIO) diet, on BL and CL mammary tumor growth, serum fatty acids, hormones, 
insulin sensitivity and adipokines as well as tissue proliferation, cyclooxygenase (COX)-2 
expression, measures of apoptotic activity, and pro- and anti-inflammatory eicosanoid 
intermediates.
Materials and Methods
Mice, diets and study design
All animal procedures were approved by the University of Texas at Austin Institutional 
Animal Care and Use Committee.
A pilot study was completed to determine the EPA+DHA concentration in the diet needed to 
achieve similar serum and erythrocyte EPA and DHA levels in mice as observed in the 
parallel human studies in women at high risk for breast cancer and receiving Lovaza 4 g/day 
[14]. For this pilot study, 14 week old female ovariectomized (surgery performed at 9 weeks 
of age) C57BL/6 mice (n=18) were purchased from Charles River (Wilmington, MA) and 
allowed to acclimate on a 12-hour light/dark cycle for one week. Mice were then placed on a 
control diet (Research Diets, New Brunswick, NJ; D12450B) for 4 weeks, then randomly 
assigned (n=6 per group) to receive (ad libitum) the control diet, a low dose EPA+DHA diet 
(0.025%, Research Diets, D11051403) or a high dose EPA+DHA diet (0.05%, Research 
Diets, D11051404) for 8 weeks. Lovaza capsules were purchased from the Kansas 
University Medical Center pharmacy, and the contents removed then mixed with diet. Diets 
were stored at 4°C in sealed bags and replaced daily to prevent oxidation. At the conclusion 
of the study, mice were killed by cervical dislocation, exsanguinated by cardiac puncture, 
and tissues were excised and flash frozen in liquid nitrogen and then stored at −80°C for 
lipid analysis.
For the mammary tumor growth study, ovariectomized female C57BL/6 mice (10 weeks of 
age; n=92) were purchased from Charles River and allowed to acclimate on the control diet 
for one week. Mice were then randomly assigned (n=23 per diet) to the control diet (10% 
kcal from fat), the control diet supplemented with 0.025% EPA+DHA (control with EPA
+DHA), a 60 kcal % fat diet (DIO; Research Diets, D12492) or a DIO diet supplemented 
with 0.025% EPA+DHA (DIO with EPA+DHA), all fed ad libitum. Diet was stored at 4°C 
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in sealed bags and replaced daily to prevent oxidation. Body weight and caloric intake were 
measured weekly. After 6 weeks on the diet treatments, a subset of mice (n=3 per diet) was 
killed for pre-tumor biological analysis. The remaining mice were orthotopically injected 
with 5×104 Wnt-1 (BL; n=10 per diet) or 5×104 M-Wnt (CL; n=10 per diet) murine 
mammary tumor cells into the fourth (abdominal) mammary fat pad. Tumors were measured 
twice weekly and in vivo tumor area was approximated using the formula πr2. When tumors 
reached 1.0 cm in any direction, all mice were fasted for 6 hours and anesthetized with 
isoflurane followed by cardiac puncture. Tumors were excised and either fixed in 10% 
neutral-buffered formalin or flash frozen in liquid nitrogen and stored at −80 °C until further 
analysis.
Wnt-1 and M-Wnt tumor cell suspensions
The Wnt-1 mammary tumor cell suspension was prepared from spontaneous mammary 
tumors excised from MMTV-Wnt-1 transgenic mice as previously described [4]. M-Wnt 
cells were clonally derived from a MMTV-Wnt-1 tumor cell suspension, cultured, and 
prepared for transplantation as previously described [11]. The M-Wnt cells were tested for 
species verification, karyotyping, and analysis of genomic instability and were authenticated 
by the Molecular Cytogenetics Core facility at the University of Texas MD Anderson Cancer 
Center, Houston, TX in March 2011.
Body composition, glucose tolerance and serum hormones
Prior to tumor implantation, body fat and lean mass were assessed by quantitative magnetic 
resonance (qMRI; Echo Instruments, Houston, TX) (n=10 per group). A glucose tolerance 
test (GTT) was done as previously described [15] after 5 weeks of dietary intervention (n=10 
per group). After 6 weeks of dietary intervention, serum was collected (following a 6-hour 
fast) from the retro-orbital venous plexus and assayed using LINCOplex® Mouse Adipokine 
Multiplex Assays (Millipore, Inc., Billerica, MA), according to the manufacturer’s 
instructions, on a BioRad Bioplex 200 analysis system (BioRad, Inc., Hercules, CA) to 
determine serum levels of insulin, leptin, and adiponectin. Serum tumor necrosis factor alpha 
(TNFα) and monocyte chemoattractant protein 1 (MCP-1) levels were measured using 
Mouse Singleplex assays (BioRad) on the BioPlex analyzer. Total circulating levels of 
insulin-like growth factor (IGF)-I and IGF binding protein 3 (IGFBP3) were measured using 
Mouse/Rat IGF-I and Mouse IGFBP3 Quantikine ELISA Kits (R&D System, Inc., 
Minneapolis, MN) per manufacturer’s instructions on a BioTek Synergy plate reader 
(Winooski, VT). Blood collected by tail nick following a 6-hour fast was analyzed for 
fasting glucose using an Ascencia Elite XL 3901G glucose analyzer (Bayer Corporation, 
Mishawaka, IN).
Histopathology and immunohistochemical staining
Paraffin embedded tumor tissue (6 per group, randomly selected) was cut into 4 μm thick 
sections and processed for either hematoxlin and eosin (H&E) staining or 
immunohistochemical (IHC) analysis as previously described [16]. Slides were then 
incubated with the following primary antibodies (source, dilution, and incubation conditions 
presented parenthetically): Ki-67 (Dako; 1:200, 4°C overnight); phospho-p65Ser276 (Santa 
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Cruz; 1:100, overnight at 4°C), cleaved caspase-3 (R&D systems; 1:500, 30 minutes at RT) 
and COX-2 (Cayman, 1:500, 1 hour at RT). Finally, slides were incubated with Dako 
EnVision™ labeled polymer for 30 minutes at RT, followed by incubation with Dako 
diaminobenzidine and counterstained with hematoxylin. Tumor slides were scanned using 
the ScanScope XT (Aperio Technologies, Vista, CA). Quantitation was performed using the 
Aperio Digital Pathology Platform. Briefly, 3-4 representative areas/tumor were viewed at 
20-40× magnification and scored based upon the percentage of cells with positive staining or 
by stain intensity using individually developed scoring algorithms.
Serum and erythrocyte lipid analysis
The serum and erythrocyte fatty acid composition in pilot study mice was measured using a 
modified Folch et al. method [17] as previously described [18]. Fatty acid methyl esters were 
isolated following transmethylation with boron trifluoride-methanol and analyzed by gas 
chromatography using a Varian 3900 (Agilent Technologies, Santa Clara, CA). To analyze 
the phospholipid content of the erythrocyte samples, equal volumes of sample from mice in 
the same group were combined. Fatty acid levels are reported as weight % of total 
phospholipid (for erythrocytes) and weight % of total cholesterol ester and phospholipid (for 
serum).
Eicosanoid analysis
Eicosanoids in the mammary tumor and visceral adipose tissues were extracted and analyzed 
by liquid chromatography/tandem mass spectroscopy (LC/MS/MS) using the modified 
method described previously [19]. LC/MS/MS analyses were performed using an Agilent 
6460 triple quadrupole (QqQ) mass spectrometer (Agilent Technologies) equipped with an 
Agilent 1200 binary pump high-performance liquid chromatography system as described 
previously [20].
Statistics
Fatty acid compositions in serum and erythrocytes, plus fatty acid derivatives in adipose and 
tumor tissue are described by means ± SEM; but comparison between groups is assessed 
with the non-parametric Mann-Whitney test due to small sample sizes and non-normal 
distributions. All other data are presented as means ± SEM and analyzed by 1-way analysis 
of variance (ANOVA) followed by Tukey’s post-hoc test with the exception of feed intake, 
body weight, in vivo tumor area and glucose tolerance test which were analyzed by repeated 
measures ANOVA. P ≤ 0.05 was considered statistically significant.
Results
EPA+DHA supplementation increases serum and erythrocyte EPA and DHA levels and 
modulates visceral adipose tissue accumulation of inflammatory lipid derivatives
In the dose-establishing pilot study, serum and erythrocyte fractions were analyzed for EPA, 
DHA, arachidonic acid (AA) and total n-3 and n-6 fatty acids from mice that consumed diets 
supplemented with EPA+DHA (0%, 0.025% or 0.05% of total diet) for 8 weeks (Table 1). 
EPA levels significantly increased in both the sera (P<0.05) and erythrocyte (P<0.05) 
phospholipid fractions (Table 1) in response to both EPA+DHA diets although the higher 
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dose (0.05%) did not increase EPA accumulation relative to lower supplementation levels 
(0.025%). DHA levels increased in the erythrocytes in response to both levels of EPA+DHA 
supplementation, but the increase was only statistically significant for the higher dose 
(0.05%) (P<0.05). As the proportion of arachidonic acid (AA) decreased in the sera and 
erythrocyte fractions, the ratio of EPA + DHA to AA significantly increased, as did the total 
n-3 to n-6 ratio (P<0.05). EPA+DHA supplementation (n=2 randomly selected per group) in 
general reduced accumulation of COX and LOX derived AA pro-inflammatory mediators, 
including 6-keto prostaglandin (PG)F1α, thromboxane (TX)B2, PGF2α, PGE2, PGD2, 12-
hydroxyeicosatetraenoic acid (12-HETE), and 5-HETE, and substantially increased EPA 
derived COX-2 metabolites, such as PGE3, in visceral adipose tissue. Moderate reductions 
of 13-hydroxyoctadecadienoic acid (13-HODE) and 15-HETE (metabolites of omega-6 fatty 
acids), were also observed in the visceral adipose tissue from mice treated with EPA+DHA 
compared to the control group (Supplementary Table 1).
EPA+DHA supplementation does not alter body composition, body weight or feed intake
Body composition was analyzed by qMRI for lean mass and fat mass after 5 weeks on diet 
and prior to tumor implantation. Control (29.3 ± 1.0%) and control with EPA+DHA (32.2 
± 1.0%) mice had significantly less fat mass relative to DIO (48.2 ± 0.8%) and DIO with 
EPA+DHA (47.2 ± 1.0%) (P<0.001, Figure 1A). Average body weight is shown for the first 
6 weeks on dietary intervention and prior to tumor implantation. Mice that consumed the 
DIO diets (+/− EPA+DHA) were significantly heavier relative to mice fed the control diet 
(+/− EPA+DHA) (P<0.001) at 6 weeks (Figure 1B) and throughout the remainder of the 
study (data not shown). The DIO and DIO with EPA+DHA dietary regimens resulted in a 
significantly greater average caloric consumption compared to the control and control with 
EPA+DHA groups for the first 6 weeks of dietary intervention (P<0.001, Figure 1C) and 
throughout the remainder of the study (data not shown).
EPA+DHA supplementation modulates production of inflammatory fatty acid derivatives
The accumulation of pro-inflammatory and anti-inflammatory fatty acid metabolites was 
assessed in Wnt-1 and M-Wnt tumor tissue (Table 2). The DIO diet, relative to the control 
diet, led to increased accumulation of 5-HETE and 18-Hydroxyeicosapentaenoic acid 
(HEPE) within M-Wnt tumor tissue (P<0.0.5), but did not significantly modify 5-HETE 
within Wnt-1 tumors (18-HEPE was not assayed). EPA+DHA supplementation to the DIO 
diet significantly increased PGE3 in M-Wnt mammary tumors (P<0.05). . EPA+DHA did 
not significantly change other fatty acid metabolites in the mammary tumors of DIO mice, 
but there were numerous instances where supplementation reversed a trend resulting from 
the DIO diet. For example, TXB2, PGD2, 15-HETE, and 5-HETE were all decreased in M-
Wnt mammary tumors, and 6ketoPGF1α, TXB2, PGF2α, PGE2, PGD2, 15-HETE, 12-
HETE, and 5-HETE were all reduced in Wnt-1 tumors with supplementation. In visceral 
adipose tissue, mice receiving either the control or DIO diets with EPA+DHA had 
significantly elevated levels of 18-HEPE compared to control without EPA+DHA (P<0.05). 
PGE3 was increased with EPA+DHA supplementation to either diet, but the increase was 
only statistically significant for the control with EPA+DHA mice (P<0.0.5) (Table 3).
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EPA+DHA supplementation improves glucose tolerance and adipokine levels in DIO mice
Fasting serum leptin levels were higher in DIO mice and DIO with EPA+DHA mice 
compared to control and control with EPA+DHA (both P<0.001, Figure 2A). Adiponectin 
concentrations were lower in DIO mice relative to all other groups (Figure 2B), and DIO 
mice also had a significantly higher leptin to adiponectin ratio compared to DIO with EPA
+DHA (P<0.05), and compared to control and control with EPA+DHA mice (P<0.001, 
Figure 2C). There were no significant differences between groups in total IGF-1 levels 
(Figure 2D). However, fasting blood glucose was significantly greater in mice on the DIO 
and DIO with EPA+ DHA regimens compared to control mice (P<0.05) and mice on the 
control with EPA+DHA regimen (P<0.005) (Figure 2E). Mice receiving the DIO with EPA
+DHA regimen had significantly better glucose tolerance than DIO mice, but worse 
tolerance in comparison to the control and control with EPA+DHA mice (P<0.05, Figure 
2F). TNFα, MCP-1 and insulin (Supplemental Figure 1A-C) were not significantly altered 
by EPA+DHA supplementation regardless of diet or tumor type. IGFBP3 and bioavailable 
IGF-1, indicated by the ratio of total IGF-1 to IGFBP3, were also not significantly altered by 
EPA+DHA supplementation (Supplemental Figure 1D-E).
EPA+DHA supplementation reduces rate of Wnt-1 and M-Wnt murine mammary tumor 
growth in obese mice
M-Wnt mammary tumors grew significantly faster than Wnt-1 tumors (median time to 1 cm 
tumor is ~4 weeks after M-Wnt tumor transplant vs. ~9 weeks after Wnt-1 tumor transplant) 
(P<0.001, Figure 3A). For this reason, mice with M-Wnt tumor transplants were killed at 4 
weeks and mice with Wnt-1 tumor transplants were killed at 9 weeks post implantation. EPA
+DHA supplementation reduced tumor area of M-Wnt and Wnt-1 tumors in obese mice 
compared with the DIO regimen alone (Figure 3A). The average DIO with EPA+DHA 
mouse tumor weight (M-Wnt, 1.14 ± 0.09 g; Wnt-1, 0.43 ± 0.1 g) was significantly less than 
the average DIO mouse tumor weight (M-Wnt, 1.63 ± 0.07 g; Wnt-1, 1.26 ± 0.1 g) (both 
P<0.05, Figure 3B). However, tumors in the control with EPA+DHA mice (M-Wnt, 0.88 
± 0.08 g; Wnt-1, 0.36 ± 0.2 g) were non-significantly different in weight relative to their 
non-supplemented counterparts (M-Wnt, 0.97 ± 0.1 g; Wnt-1, 1.03 ± 0.2 g) (Figure 3B). 
Since the strongest and most consistent anticancer effects of EPA+DHA were observed in 
DIO mice, all subsequent comparisons will be made between the control, DIO, and DIO 
with EPA+DHA groups.
H&E staining of M-Wnt tumors reveals accumulation of adipocytes, which were not present 
in Wnt-1 tumors (Figure 3C). Although it is not clear whether adipocytes differentiated from 
the tumor initiating cell-enriched M-Wnt cell population or whether there was increased 
recruitment of adipocytes from local mammary fat pad tissue, it is apparent that dietary 
energy balance modulated the accumulation of adipocytes within the tumor tissue. 
Specifically, tumors from DIO mice had much greater accumulation of adipocytes than 
tumors from control mice. Moreover, EPA+DHA supplementation reduced the DIO-
associated increase in prevalence and size of adipocytes within the tumor tissue (Figure 3C).
The influence of dietary interventions on cell proliferation was assessed in tumor tissues by 
IHC staining against Ki-67 (Figure 3C). Tumor cell proliferation rates for the M-Wnt and 
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Wnt-1 tumors from control-fed mice varied widely, with 23.0 ± 2.5% and 73.4 ± 2.8% 
positive cells, respectively. The DIO diet did not further increase the proliferation rate in the 
highly proliferative Wnt-1 tumors (75.4 ± 1.5% positive cells) relative to control mice. 
However, M-Wnt tumors in the DIO mice had double the proliferation rate (47.3 ± 7.1% 
positive cells, P<0.05) in comparison to control mice. Wnt-1 tumors from DIO with EPA
+DHA-treated mice, relative to DIO without EPA+DHA, showed significantly reduced 
tumor Ki-67 staining (64.2 ± 1.9% positive cells, P<0.005). In contrast, M-Wnt tumors from 
DIO with EPA+DHA-treated mice (47.9 ± 4.5% positive cells) showed no significant 
reduction in proliferation relative to DIO without supplementation. EPA+DHA did not 
significantly alter the expression of several cell proliferation-related proteins, including: 
phospho-mTORSer2448, mTOR, phospho-S6 ribosomal proteinSer235/236, cyclin D1, and 
phospho-AktS473 (data not shown).
EPA+DHA supplementation increases cleaved caspase-3 and reduces COX-2 and 
phospho-p65 in DIO mouse tumors
The influence of dietary interventions on markers of cellular apoptosis and inflammation 
was assessed in tumor tissues by IHC staining against cleaved caspase-3, COX-2 and 
phospho-p65 (Figure 4A-B). Cleaved caspase-3 staining, a marker of apoptosis, clustered in 
small groups rather than throughout the entire tumor sections; therefore, average “positive 
staining island” area was measured. M-Wnt tumors from the DIO with EPA+DHA group 
had significantly more staining for cleaved caspase-3 (3.18 ± 1.2 μm2) than M-Wnt tumors 
from DIO without supplementation (1.04 ± 0.27 μm2, P<0.05) or control mice (0.8 ± 0.4 
μm2, P<0.05). The DIO with EPA+DHA regimen also significantly increased staining for 
cleaved caspase-3 in Wnt-1 tumors (6.1 ± 2.6 μm2) relative to DIO (2.1 ± 1.1 μm2, P<0.05) 
or control (2.07 ± 1.0 μm2, P<0.05) diets. Expression of COX-2, the enzyme responsible for 
the production of prostanoids from 20 carbon polyunsaturated fatty acids [21], and phospho-
p65, the active form of a subunit of the pro-inflammatory NFκB transcription factor [22], 
were analyzed for the percentage of total positive staining per tumor section. COX-2 and 
phospho-p65 expression levels were significantly increased with the DIO regimen in the 
Wnt-1 (P<0.001, P<0.0001 respectively) and M-Wnt (P<0.01, P<0.05 respectively) tumors, 
and this DIO-associated increase in staining was reduced with EPA+DHA supplementation 
(P<0.05). EPA+DHA did not significantly alter staining for the macrophage markers CD31 
or F4/80 regardless of diet group or tumor type (data not shown).
Discussion
We found that supplementation with EPA+DHA ethyl esters reduced tumor growth in obese 
immunocompetent mice orthotopically transplanted with aggressive types of TNBC (BL or 
CL). The anticancer effects of EPA+DHA administration were associated with: 1) reduced 
production of inflammatory signaling molecules and lowered expression of key 
inflammatory proteins within mammary tumor tissue; 2) normalization (to control levels) of 
assorted obesity-associated factors, including leptin:adiponectin ratio and insulin sensitivity, 
in DIO mice without normalization of body weight; and 3) induced expression of the 
apoptotic protein cleaved caspase-3. Our results suggest that EPA+DHA supplementation 
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may be a promising strategy for the inhibition of hormone receptor-negative breast cancer 
progression in obese postmenopausal women.
To our knowledge this is the first study to model the effects of obesity, with and without EPA 
and DHA supplementation, on two very aggressive breast cancer subtypes (BL and CL) with 
poor prognosis and few therapeutic options. Wnt/beta-catenin pathway activation is known 
to be enriched in human TNBCs and is associated with poor outcome [23], so our murine 
models of Wnt-driven BL and CL are relevant to human TNBC. The M-Wnt cell line (which 
when orthotopically transplanted generate tumors with molecular profiles mimicking human 
CL) was subcloned from Wnt-1 cells (which when orthotopically transplanted generate 
tumors reflective of human BL breast tumors). Thus, our murine models of BL and CL 
breast cancer share the same genetic background but differ in molecular and clinical 
characteristics. Another important aspect of our Wnt-1 and M-Wnt tumor models is the use 
of C57BL/6 mice, which are syngeneic to our Wnt-1 and M-Wnt cells. Unlike most other 
commonly used genetic backgrounds for BL and CL mammary tumor models, C57BL/6 
mice have a fully functioning immune system and are sensitive to DIO. This facilitates the 
characterization of the effects of obesity and omega-3 fatty acid supplementation on 
inflammation, a hallmark of cancer [24] that is inherent in obese individuals and that cannot 
be adequately modeled in immunodeficient or obesity-resistant mouse models. Moreover, 
the tissue levels of DHA and EPA attained in this study are in the physiological range 
[25-26] and were matched with women receiving daily supplementation with 4g of EPA
+DHA per day (14). This dose of EPA+DHA is considered safe and well tolerated in 
postmenopausal women and is currently approved for treatment of hypertriglyceridemia by 
the FDA [27].
Insulin resistance, glucose intolerance, elevated leptin levels, and low adiponectin levels are 
associated with the metabolic syndrome and are established risk factors for breast cancer 
[28-31]. As normal cells become neoplastic there is a switch in glucose metabolism from 
oxidative phosphorylation to oxidative glycolysis in order to supply essential 
macromolecules for new cell production [32]. The increased proliferation rate associated 
with most cancer cells can only be sustained by a constant supply of glucose, sometimes 
referred to as glucose addiction. Here, we demonstrated a decreased leptin:adiponectin ratio 
and improved glucose tolerance in DIO mice with EPA+DHA supplementation, relative to 
DIO mice without supplementation, as previously seen with other studies testing dietary 
regimens containing high omega-3 fatty acids [33-34].
Regardless of tumor type, EPA+DHA in DIO mice reduced (relative to DIO alone) tumorla 
staining of two important regulators of inflammatory signals: COX-2 (an enzyme that 
catalyzes the conversion of arachidonic acid to PGE2) and phospho-p65 (the major subunit 
of the cytokine-regulating transcription factor NF-κB) [35]. EPA+DHA also enhanced 
staining for cleaved caspase-3, a pro-apoptotic protein that is responsible for chromatin 
condensation and DNA fragmentation [36]. Taken together, these findings suggest that EPA
+DHA can dampen inflammation and promote apoptosis in Wnt-1 and M-Wnt tumors. 
Supplementation with EPA+DHA did not significantly reduce serum levels of obesity-
associated inflammatory markers unrelated to polyunsaturated fatty acid metabolism in the 
DIO mice, including TNFα and MCP-1, but these cytokines were also not significantly 
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elevated in the DIO mice compared to control. It may be that the six week obesity induction 
period in this study was too short to produce significant increases in the circulating levels of 
these cytokines. Given that all of the anti-inflammatory effects of EPA+DHA 
supplementation demonstrated in this study involved markers that had been significantly 
changed by obesity in the DIO mice, it is possible that EPA+DHA may only reduce levels of 
these cytokines if they are significantly elevated by obesity or another cause. In support of 
this hypothesis, there was a trend towards increased concentrations of both TNFα and 
MCP-1 in the DIO mice that was reduced by EPA+DHA supplementation, but these 
differences did not reach statistical significance.
While enhanced apoptosis may partially explain why EPA+DHA supplementation in obese 
mice significantly reduced M-Wnt (CL) and Wnt-1 (BL) tumor size and weight, EPA+DHA 
also significantly decreased Ki-67 within Wnt-1 mammary tumors, which had relatively 
high proliferation rates (in comparison to the M-Wnt tumors) that were not further enhanced 
by obesity. In contrast, Ki-67 in M-Wnt mammary tumors was not affected by EPA+DHA 
supplementation, but was elevated in the tumors of DIO mice relative to control. These 
differences in proliferation response to obesity and EPA+DHA between tumor types are 
likely related to the difference in baseline proliferation rates. However, despite the inhibitory 
effects of EPA+DHA on Wnt-1 tumor proliferation, supplementation had no significant 
impact on the levels of key proliferative proteins (phosphor-mTORSer2448, mTOR, 
phosphor-S6 ribosomal proteinSer235/236, cyclin D1, phosphor-AktS473) in either model of 
breast cancer. Thus, combining EPA+DHA with practical weight loss interventions or agents 
that better target proliferation and survival pathways, such as the mTOR pathway, may more 
effectively suppress BL or CL breast cancer progression [37-39].
A reduction in obesity-driven pro-inflammatory signaling may contribute to the reduced 
tumor progression in DIO mice, but not control mice. Chronic inflammation, commonly 
associated with obesity, is linked with increased risk for breast cancer [40]. The 
inflammatory microenvironment exerts tumor-promoting effects specifically via genetic 
instability and cellular proliferation, survival and angiogenesis [41-42]. In this study, EPA
+DHA supplementation increased the anti-inflammatory fatty acid derivative PGE3 in M-
Wnt mammary tumors. Additionally, other EPA and DHA derivatives in both tumor types 
trended towards a reduction in pro-inflammatory signaling in response to EPA+DHA, 
although differences were not statistically significant. Tumoral staining for COX-2, the 
enzyme responsible for the production of pro-inflammatory eicosanoids from omega-6 fatty 
acids, was also significantly reduced by EPA+DHA supplementation. Selective COX-2 
inhibitors are commercially available and could potentially be used for the prevention or 
therapy of breast cancer. However, many of these drugs have been removed from the market 
or are limited in their use due to an elevated risk for cardiovascular events. In contrast, EPA
+DHA is an FDA approved drug that has shown no enhanced risk for cardiovascular events 
and in fact may be cardioprotective, as it is currently prescribed for individuals with elevated 
levels of triglycerides [43].
Increased adipocyte infiltration into breast tumors has been correlated with a worse patient 
outcome [44-45], and numerous in vivo and in vitro studies have demonstrated that cross-
talk between adipocytes and mammary cancer cells promotes greater tumor aggressiveness 
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via multiple mechanisms [46]. Previously, we have shown that DIO promotes greater M-Wnt 
tumor adipocyte accumulation in comparison to control diet [11]. This study produced 
similar results, finding that the DIO diet induces greater intra-tumoral adipocyte number and 
size relative to control. It further demonstrated that EPA+DHA supplementation partially 
prevents these DIO-related effects, suggesting that the inhibition of intra-tumoral adipocyte 
accumulation may be one additional mechanism by which EPA+DHA supplementation can 
help prevent CL breast cancer progression. In contrast, there was very low adipocyte 
accumulation in any of the Wnt-1 tumors, consistent with previous studies utilizing Wnt-1 
mammary tumor cells [4,47], and EPA+DHA thus had no impact on this variable in the 
Wnt-1 tumors. This difference between the Wnt-1 and M-Wnt tumors may be related to the 
latter’s enrichment in tumor initiating cells, which may have increased secretion of 
chemoattractants that recruit adipocytes to t he tumors and/or may have the potential to 
differentiate into adipocytes. Both possibilities are being explored in current studies.
In conclusion, EPA+DHA ethyl ester supplementation countered the DIO-induced 
acceleration of tumor growth in murine CL and BL models of TNBC. The anticancer effects 
of EPA+DHA were associated with improved glucose tolerance, decreased serum 
leptin:adiponectin ratio, decreases in tumoral pro-inflammatory markers, and increased 
tumoral cleaved caspase-3. These findings, in combination with parallel studies in women 
[14], suggest EPA+DHA supplementation should be further explored for reducing the 
burden of TNBC (including BL and CL) in obese women.
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EPA+DHA supplementation does not alter body composition, body weight or feed intake. A, 
body composition is assessed as the percentage of fat and lean tissue at 5 weeks, B, average 
body weight (1-6 weeks on diet) and C, average kcals consumed per day (1-6 weeks on 
diet); n=10 per group. Means ± SEM, statistically significant (P<0.05) differences are 
indicated by different letters.
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The effect of diet regimens on serum hormones. A, Leptin, B, Adiponectin, C, 
Leptin:Adiponectin ratio, D, IGF-1, E, Glucose, F, GTT conducted at 6 weeks on diet, n=10 
per group. Means ± SEM, statistically significant (P<0.05) differences are indicated by 
different letters.
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The effect of a DIO regimen +/− EPA+DHA supplementation on tumor growth. A, in vivo 
M-Wnt (claudin—low) and Wnt-1 (basal-like) mammary tumor growth, n=10 per group. B, 
M-Wnt and Wnt-1 average ex vivo tumor weight, n=10 per group. C, representative 
photomicrographs of pathology and IHC staining of tumors for Ki-67 and bar graphs 
representing the Aperio image quantitation, scale bars indicate 100 μm, n=6 per group. 
Means ± SEM, statistically significant (P<0.05) differences are indicated by different letters.
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The effect of a DIO regimen +/− EPA+DHA supplementation on IHC tumoral staining. A, 
representative photomicrographs of pathology and IHC staining of tumors for cleaved 
caspase-3, COX-2 and phospho-p65. B, bar graphs representing the Aperio image 
quantitation, scale bars indicate 100 μm, n=6 per group. Means ± SEM, statistically 
significant (P<0.05) differences are indicated by different letters.
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Table 1















Erythrocyte EPA 0.19 ± 0.01a 2.53 ± 0.28b 1.41 ± 0.11b
Serum EPA 0.16 ± 0.02a 1.66 ± 0.09b 1.05 ± 0.08b
Erythrocyte DHA 5.59 ± 0.52a 7.86 ± 0.90 7.99 ± 0.81b
Serum DHA 5.01 ± 0.38 5.13 ± 0.17 5.51 ± 0.32
Erythrocyte AA 14.5 ± 1.01a 9.06 ± 0.92b 10.5 ± 0.80b
Serum AA 11.6 ± 0.91a 5.47 ± 0.58b 7.59 ± 0.51b
Erythrocyte (EPA + DHA):AA 0.40 ± 0.01a 1.16 ± 0.09b 0.89 ± 0.03b
Serum (EPA + DHA):AA 0.45 ± 0.01a 1.31 ± 0.15b 0.88 ± 0.05b
Erythrocyte n-3: n-6 0.25 ± 0.01a 0.60 ± 0.04b 0.52 ± 0.02b
Serum n-3: n-6 0.31 ± 0.01a 0.52 ± 0.06b 0.43 ± 0.02b
Erythrocyte (% total phospholipid) and serum (% total cholesterol ester and phospholipid) levels of eicosapentaenoic acid (EPA), docosahexaenoic 
acid (DHA), arachidonic acid (AA), the ratio of EPA + DHA: AA, and the ratio of n-3: n-6 fatty acids. Statistically significant (P≤0.05) differences 
are indicated by different letters, e.g.: a group designated with is a different than a group designated with b; but two groups with b are not different.
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M-Wnt 6ketoPGF1α 12.2 ± 4.7 3.9 ± 1.7a 12.7 ± 3.3b 22.9 ± 8.9b
Wnt-1 6ketoPGF1α 3.5 ± 1.3 3.2 ± 1.8 9.4 ± 6.1 4.2 ± 2.3
M-Wnt TXB2 44.6 ± 12.7 13.5 ± 5.3 128.2 ± 45.2 80.4 ± 23.1
Wnt-1 TXB2 3.9 ± 1.4 1.2 ± 0.4 7.9 ± 4.8 3.2 ± 1.4
M-Wnt PGF2α 3.3 ± 0.9a 1.1 ± 0.7a 8.8 ± 3.3 7.6 ± 1.8b
Wnt-1 PGF2α 1.9 ± 0.8 0.23 ± 0.06 3.1 ± 1.9 1.7 ± 0.8
M-Wnt PGE2 9.0 ± 2.8 4.4 ± 1.0a 10.0 ± 2.8 13.6 ± 1.6b
Wnt-1 PGE2 8.6 ± 3.7 2.3 ± 0.9 18.3 ± 9.4 5.4 ± 2.3
M-Wnt PGE3 0.11 ± 0.04 0.085 ± 0.037a 0.071 ± 0.017a 0.25 ± 0.08b
Wnt-1 PGE3 0.08 ± 0.03 0.03 ± 0.01 0.14 ± 0.07 0.15 ± 0.09
M-Wnt PGD2 144.2 ± 51.1 99.8 ± 42.4a 385.1 ± 62.4b 220.6 ± 67.3
Wnt-1 PGD2 5.7 ± 2.3 1.4 ± 0.6 8.9 ± 4.4 4.3 ± 1.6
M-Wnt 13HODE 40.3 ± 10.3 12.4 ± 6.7a 47.9 ± 17.6 99.0 ± 30.2b
Wnt-1 13HODE 2.6 ± 1.1a 2.1 ± 1.7a 12.8 ± 5.3 11.0 ± 2.6b
M-Wnt 15HETE 9.5 ± 2.8 3.2 ± 0.8a 28.4 ± 9.5b 17.5 ± 4.9b
Wnt-1 15HETE 1.3± 0.5 0.61 ± 0.17a 4.1 ± 1.9b 2.1 ± 0.6
M-Wnt 12HETE 28.6 ± 9.8 12.2 ± 3.8a 31.5 ± 9.8 32.9 ± 8.1b
Wnt-1 12HETE 21.9 ± 6.8 5.6 ± 1.5a 39.3 ± 17.6 20.1 ± 4.8b
M-Wnt 5HETE 3.2 ± 0.7a 2.1 ± 0.5a 28.9 ± 11.9b 8.9 ± 2.6b
Wnt-1 5HETE 0.65 ± 0.15 0.60 ± 0.19 1.6 ± 0.5 0.87 ± 0.19
M-Wnt 18HEPE 0.004 ± 0.004a 0.038 ± 0.016b 0.037 ± 0.012b 0.053 ± 0.030
Wnt-1 18HEPE NA NA NA NA
6-ketoPGF1α, 6-keto prostaglandin F1α; TXB2, thromboxane B2; PGE3, prostaglandin E3; PGF2α, prostaglandin F2α; PGE2, prostaglandin E2; 
PGD2, prostaglandin D2; 13HODE, 13-hydroxyoctadecadienoic acid; 15HETE, 15-hydroxyeicosatetraenoic acid; 12HETE, 12-
hydroxyeicosatetraenoic acid; 5HETE, 5-hydroxyeicosatetraenoic acid; 18HEPE, 18-hydroxyeicosapentaenoic acid. Statistically significant 
(P≤0.05) differences are indicated by different letters, e.g., a group designated with is a different than a group designated with b; but two groups 
with a are not different.
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Table 3













6ketoPGF1α 148 ± 58 144 ± 33 211 ± 103 47.6 ± 47
TXB2 6.7 ± 1.5 5.4 ± 2.2 10.0 ± 5.3 4.2 ± 4.2
PGF2α 11.3 ± 3.5 8.7 ± 2.7 22.8 ± 11.0 4.4 ± 3.5
PGE2 35.8 ± 9.9 31.3 ± 6.6 51.4 ± 34.5 9.3 ± 9.2
PGD2 47 ± 22 37 ± 11 199 ± 92 113 ± 106
13HODE 973 ± 456 648 ± 123 1175 ± 268 769 ± 542
15HETE 171 ± 61 85 ± 5 159 ± 39 84 ± 62
12HETE 753 ± 216 400 ± 72 776 ± 158 320 ± 230
5HETE 11.0 ± 1.2 8.6 ± 3.1 15.6 ± 3.7 18.8 ± 12.6
18-HEPE 0.16 ± 0.08a 2.34 ± 0.44b 0.79 ± 0.22b 7.46 ± 6.32b
PGE3 0.29 ± 0.06a 3.35 ± 0.94b 0.73 ± 0.47 1.07 ± 0.60
6-ketoPGF1α, 6-keto prostaglandin F1α; TXB2, thromboxane B2; PGE3, prostaglandin E3; PGF2α, prostaglandin F2α; PGE2, prostaglandin E2; 
PGD2, prostaglandin D2; 13HODE, 13-hydroxyoctadecadienoic acid; 15HETE, 15-hydroxyeicosatetraenoic acid; 12HETE, 12-
hydroxyeicosatetraenoic acid; 5HETE, 5-hydroxyeicosatetraenoic acid; 18HEPE, 18-hydroxyeicosapentaenoic acid. Statistically significant 
(P≤0.05) differences are indicated by different letters, e.g., a group designated with is a different than a group designated with b; but two groups 
with b are not different.
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